Cilostazol

Heart Disease

Volumn 1, Issue 3, 1999, Pages 182-186

  Cheng, Judy W M ^a,b  

^a LONG ISLAND UNIVERSITY   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CILOSTAZOL; PHOSPHODIESTERASE INHIBITOR; TETRAZOLE DERIVATIVE; VASODILATOR AGENT;

DRUG CONTRAINDICATION; HUMAN; INTERMITTENT CLAUDICATION; REVIEW;

HUMAN; INTERMITTENT CLAUDICATION; PHOSPHODIESTERASE INHIBITORS; TETRAZOLES; VASODILATOR AGENTS;

EID: 0033157296     PISSN: 1521737X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Murabito JM, D'Agostino RB, Silbershatz H, Wilson PWF. Intermittent claudication: a risk profile from the Framingham Heart Study. Circulation 1997; 96:44-49.
2. Santilli JD, Rodnick FE, Santilli SM. Claudication: diagnosis and treatment. Am Fam Phys 1996;53:1245-1253.
3. Bajwa TK, Shalev YA, Gupta A, Khalid MD, Maussavi N. Peripheral vascular disease: part 1. Curr Probl Cardiol 1998;23:245-297.
4. McNamara DB, Champion HC, Kadowitz PJ. Pharmacological management of peripheral vascular disease. Surg Clin North Am 1998;78:447-464.
5. Gibbons GH, Dzau VJ. The emerging concept of vascular remodeling. N Engl J Med 1994;330:1431-1438.
6. Basha BJ, Sowers JR. Atherosclerosis: an update. Am Heart J 1995;131:1192-1202.
7. Zeiher AM, Drexler H, Saurbier B, Just H. Endothelium mediated coronary blood flow modulation in humans: effects of age, atherosclerosis, hypercholesterolemia, and hypertension. J Clin Invest 1993;92:652-662.
8. Chobanian AV. Pathophysiology of atherosclerosis. Am J Cardiol 1992;70: 3G-7G.
9. Hess H, Mietaschik A, Deichsel G. Drug-induced inhibition of platelet function delays progression of peripheral occlusive arterial disease: a prospective, double-blind arteriographically controlled trial. Lancet 1985;1:416-419.
10. Balsano F, Coccheri S, Libretti A, Nenci GG, Catalano M, Fortunato G, et al. Ticlopidine in the treatment of intermittent claudication: a 21 month double-blind trial. J Lab Clin Med 1989;114:84-91.
11. Boissel JP, Peyrieux JC, Destors JM. Is it possible to reduce the risk of cardiovascular events in subjects suffering from intermittent claudication of the lower limbs? Thromb Haemost 1989;62:681-685.
12. Antiplatelet Trialists Collaboration. Collaborative overview of randomized trials of antiplatelet therapy. I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994;308:81-106.
13. CAPRIE Steering Committee. A randomized, blinded trial of clopidogrel versus aspirin in patients at risk of ischemic events. Lancet 1996;348:1329-1339.
14. Radack K, Wyderski RJ. Conservative management of intermittent claudication. Ann Intern Med 1990;113:135-146.
15. Jackson MR, Clagett GP. Antithrombotic therapy in peripheral arterial occlusive disease. Chest 1998;114:666S-682S.
16. Boccalon H. Intermittent claudication in older patients: practical treatment guidelines. Drugs Aging 1999;14:247-259.
17. Retter AS. Carnitine and its role in cardiovascular disease. Heart Disease 1999; 1:108-113.
18. Coffman J. Drug treatment of peripheral vascular disease. In, Frishman WH, Sonnenblick EH (eds.): Cardiovascular Pharmacotherapeutics. New York: McGraw Hill, 1997;1185-1194.
19. Perry MJ, Higgs GA. Chemotherapeutic potential of phosphodiesterase inhibitors. Curr Opin Chem Biol 1998;2:472-481.
20. Spina D, Landells LJ, Page CP. The role of theophylline and phosphodiesterase-4 isoenzyme inhibitors as antiinflammatory drugs. Clin Exp Allerg 1998; 28(suppl 3):24-34.
21. Sonnenblick EH, LeJemtel TH, Frishman WH. Digitalis preparations and other inotropic agents. In, Frishman WH, Sonnenblick EH (eds.): Cardiovascular Pharmacotherapeutics. New York: McGraw Hill, 1997;237-251.
22. Sorkin EM, Markham A. Cilostazol. Drugs Aging 1999;14:63-71.
23. Cooke J. The pathophysiology of peripheral arterial disease: rational targets for drug intervention. Vasc Med 1997;2:227-230.
24. Elam MB, Heckman JR, Crouse DB, Hunninghakc DB, Herd JA, Davidson M, et al. Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arterioscl Thromb Vasc Biol 1998;18: 1942-1947.
25. Suri A, Forbes WP, Bramer SL. Pharmacokinetics of multiple-dose oral cilostazol in middle-age and elderly men and women. J Clin Pharmacol 1998;38:144-150.
26. Money SR, Herd A, Isaacsohn JL, Davidson M, Cutler B, Heckman J, et al. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. J Vasc Surg 1998;27:267-275.
27. Dawson DL, Cutler BS, Meissner MH, Strandness E. Cilostazol has beneficial effects in treatment of intermittent claudication. Circulation 1998;98:678-686.
28. Dawson DL, Beebe HG, Davidson MH, Chinoy DA, Herd JA, Hiatt WR, et al. Cilostazol or pentoxifylline for claudication? (abstract). Circulation 1998; 98(suppl 1):I-12.
29. Cilostazol for intermittent claudication. Med Lett 1999;41:44-46.
30. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, et al. and the PROMISE Study Research Group. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 1991;325:1468-1475.
31. Cohn JN, Goldstein SO, Greenberg BH, Orell BH, Bourge RC, Jaski BE, et al. and the Vesnarinone Trial Investigators. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. N Engl J Med 1998; 339:1810-1816.
32. Plavix. Med Lett 1998;40:59.
33. Frishman WH, Chiu R, Landzberg BR, Weiss M. Medical therapies for the prevention of restenosis following percutaneous coronary interventions. Curr Probl Cardiol 1998;23:533-640.
34. Tsuchikane E, Fukahara A, Kobayashi T, Kirino M, Yamasaki K, Kobayashi T. et al. Impact of Cilostazol on restenosis after percutaneous coronary balloon angioplasty.
35. Tsuchikane E, Katoh O, Sumitsuji S, Fukuhara A, Funamoto M, Otsuji S, et al. Impact of cilostazol on intimal proliferation directional coronary atherectomy. Am Heart J 1998;135:495-502.
36. Kunishima T, Musha H, Eto F, Iwasaki T, Nagashima J, Masui Y, et al. A randomized trial of aspirin versus cilostazol therapy after successful coronary stent implantation. Clin Ther 1997;19:1058-1066.
37. Adis International, a Wolters Kluwer Co. Will Cilostazol improve care for patients with intermittent claudication? Drugs Ther Perspect 1999;14(1):1-5.